Sharh maqola

Targeting GSK3 and Associated Signaling Pathways Involved in Cancer

Przemysław DudaDepartment of Molecular Physiology and Neurobiology, University of Wrocław, Sienkiewicza 21, 50-335 Wroclaw, PolandShaw M. AkulaDepartment of Microbiology and Immunology, Brody School of Medicine at East Carolina University, Greenville, NC 27858, USAStephen L. AbramsDepartment of Microbiology and Immunology, Brody School of Medicine at East Carolina University, Greenville, NC 27858, USALinda S. SteelmanDepartment of Microbiology and Immunology, Brody School of Medicine at East Carolina University, Greenville, NC 27858, USAAlberto M. MartelliDipartimento di Scienze Biomediche e Neuromotorie, Università di Bologna, 40126 Bologna, ItalyLucio CoccoDipartimento di Scienze Biomediche e Neuromotorie, Università di Bologna, 40126 Bologna, ItalyStefano RattiDipartimento di Scienze Biomediche e Neuromotorie, Università di Bologna, 40126 Bologna, ItalySaverio CandidoDepartment of Biomedical and Biotechnological Sciences—Oncological, Clinical and General Pathology Section, University of Catania, 95123 Catania, ItalyMassimo LibraDepartment of Biomedical and Biotechnological Sciences—Oncological, Clinical and General Pathology Section, University of Catania, 95123 Catania, ItalyGiuseppe MontaltoDipartimento di Promozione della Salute, Materno-Infantile, Medicina Interna e Specialistica di Eccellenza (PROMISE), University of Palermo, 90133 Palermo, ItalyMelchiorre CervelloInstitute for Biomedical Research and Innovation, National Research Council (CNR), 90133 Palermo, ItalyAgnieszka GizakDepartment of Molecular Physiology and Neurobiology, University of Wrocław, Sienkiewicza 21, 50-335 Wroclaw, PolandDariusz RakusDepartment of Molecular Physiology and Neurobiology, University of Wrocław, Sienkiewicza 21, 50-335 Wroclaw, PolandJames A. McCubreyDepartment of Microbiology and Immunology, Brody School of Medicine at East Carolina University, Greenville, NC 27858, USA

2020en

ABI

Annotatsiya

Glycogen synthase kinase 3 (GSK-3) is a serine/threonine (S/T) protein kinase. Although GSK-3 originally was identified to have functions in regulation of glycogen synthase, it was subsequently determined to have roles in multiple normal biochemical processes as well as various disease conditions. GSK-3 is sometimes referred to as a moonlighting protein due to the multiple substrates and processes which it controls. Frequently, when GSK-3 phosphorylates proteins, they are targeted for degradation. GSK-3 is often considered a component of the PI3K/PTEN/AKT/GSK-3/mTORC1 pathway as GSK-3 is frequently phosphorylated by AKT which regulates its inactivation. AKT is often active in human cancer and hence, GSK-3 is often inactivated. Moreover, GSK-3 also interacts with WNT/β-catenin signaling and β-catenin and other proteins in this pathway are targets of GSK-3. GSK-3 can modify NF-κB activity which is often expressed at high levels in cancer cells. Multiple pharmaceutical companies developed small molecule inhibitors to suppress GSK-3 activity. In addition, various natural products will modify GSK-3 activity. This review will focus on the effects of small molecule inhibitors and natural products on GSK-3 activity and provide examples where these compounds were effective in suppressing cancer growth.

Hali tarjima qilinmagan

Identifikatorlar

DOI: 10.3390/cells9051110

Iqtiboslar va manbalar

2 ta iqtibos0 ta foydalanilgan manba

Koʻrsatkichlar — AkademScholar